Thus, the objective of this study was to evaluate the change in A1C and insulin total daily dose (TDD) in a suboptimally-controlled (not achieving A1C target of ≤ 7%) type 2 diabetes population after switching to V-Go. This evidence concerns the gene INS and type 2 diabetes mellitus.